NCT05839834 (eRBCDet) is a clinical trial of Blood test in Neoplasms, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT05839834?

Interventions in NCT05839834: Blood test.

What condition does NCT05839834 study?

NCT05839834 studies Neoplasms, Cancer.

Is NCT05839834 still recruiting?

NCT05839834 is currently recruiting now. Last updated 24 July 2024.

Last reviewed 2024-07-24 · How we verify

NCT05839834: eRBCDet

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood Cell RNA-Based Cancer Detection

Recruiting now Last updated 24 July 2024

What this trial tests

trial testing Blood test in Neoplasms in 5,000 participants. Currently enrolling.

Timeline

8 February 2021

Primary endpoint
1 November 2024

8 December 2024

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	8 February 2021
Primary completion	1 November 2024
Estimated completion	8 December 2024
Sites	1 location across China

Drugs / interventions tested

Blood test — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →
Cancer — all drugs for Cancer →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 90, any sex, with Neoplasms or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Early diagnosis of cancer may provide patients with more treatment options and hopefully prolong survival. The purpose of this multi-center study is to collect peripheral blood from newly diagnosed cancer patients and healthy donors to establish a blood cell RNA-based model for the differentiation of cancer patients and healthy donors. The area under the receiver operating characteristic (AUROC), sensitivity and specificity of the test in the early detection of multiple cancers will be measured.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

RNA modifications in cancer.
Wu H, Chen S, Li X, Li Y, et al · · 2025 · cited 5× · PMID 39802639 · DOI 10.1002/mco2.70042

Verify or expand the search:

Other trials of Blood test

Trials testing the same drug.

NCT06863974 — High-throughput Omic Technology for Identification of Biomarkers of Relapsing Acute Disseminated Encephalomyelitis in Im · NA · recruiting
NCT07078435 — Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis · NA · not yet recruiting
NCT05370300 — SNAPS Breast Cancer Patient Study Breast Cancer Patients · not yet recruiting
NCT06820450 — Pilot Study to Characterize the Endometriosis Steroidome and Its Link to Endocrine Disruptors and Vaginal Dysbiosis · not yet recruiting
NCT06999785 — Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperba · NA · recruiting

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05839834 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 24 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05839834.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing